JP2025516153A5 - - Google Patents

Info

Publication number
JP2025516153A5
JP2025516153A5 JP2024562134A JP2024562134A JP2025516153A5 JP 2025516153 A5 JP2025516153 A5 JP 2025516153A5 JP 2024562134 A JP2024562134 A JP 2024562134A JP 2024562134 A JP2024562134 A JP 2024562134A JP 2025516153 A5 JP2025516153 A5 JP 2025516153A5
Authority
JP
Japan
Prior art keywords
pharmaceutical product
product according
disorder
disease
liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024562134A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025516153A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/060601 external-priority patent/WO2023203248A1/en
Publication of JP2025516153A publication Critical patent/JP2025516153A/ja
Publication of JP2025516153A5 publication Critical patent/JP2025516153A5/ja
Pending legal-status Critical Current

Links

JP2024562134A 2022-04-22 2023-04-24 Asbt阻害剤の皮下投与 Pending JP2025516153A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE2250486 2022-04-22
SE2250486-4 2022-04-22
PCT/EP2023/060601 WO2023203248A1 (en) 2022-04-22 2023-04-24 Subcutaneous administration of an asbt inhibitor

Publications (2)

Publication Number Publication Date
JP2025516153A JP2025516153A (ja) 2025-05-27
JP2025516153A5 true JP2025516153A5 (enExample) 2026-04-23

Family

ID=86330799

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024562134A Pending JP2025516153A (ja) 2022-04-22 2023-04-24 Asbt阻害剤の皮下投与

Country Status (6)

Country Link
US (1) US20230338392A1 (enExample)
EP (1) EP4511038A1 (enExample)
JP (1) JP2025516153A (enExample)
CN (1) CN119053330A (enExample)
AU (1) AU2023255249A1 (enExample)
WO (1) WO2023203248A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2586931T3 (es) 2010-11-04 2016-10-19 Albireo Ab Inhibidores de IBAT para el tratamiento de enfermedades hepáticas
MX2020013839A (es) 2018-06-20 2021-03-25 Albireo Ab Formulacion farmaceutica de odevixibat.
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
RS63899B1 (sr) 2019-02-06 2023-02-28 Albireo Ab Benzotiadiazepinska jedinjenja i njihova upotreba kao modulatora žučnih kiselina
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
BR112022010505A2 (pt) 2019-12-04 2022-09-06 Albireo Ab Compostos de benzotia(di)azepina e seu uso como moduladores do ácido biliar
EP4069359B1 (en) 2019-12-04 2024-01-03 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
AU2021379076A1 (en) 2020-11-12 2023-06-08 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
AU2021390172A1 (en) 2020-12-04 2023-06-22 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
CN120265290A (zh) * 2022-12-09 2025-07-04 阿尔比里奥公司 治疗肾脏疾病的asbt抑制剂

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9203347D0 (en) 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds
TW289757B (enExample) 1993-05-08 1996-11-01 Hoechst Ag
TW289020B (enExample) 1993-05-08 1996-10-21 Hoechst Sktiengesellschaft
TW289021B (enExample) 1993-05-08 1996-10-21 Hoechst Ag
NZ331813A (en) 1996-03-11 2001-03-30 G Benzothiepine compounds having activity as inhibitors of ileal bile acid transport and taurocholate uptake
DK0864582T3 (da) 1997-03-14 2003-09-29 Aventis Pharma Gmbh Hypolidemiske 1,4-benzothiazepin-1,1-dioxider
SE9901387D0 (sv) 1999-04-19 1999-04-19 Astra Ab New pharmaceutical foromaulations
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
PL216023B1 (pl) 2001-09-08 2014-02-28 Astrazeneca Ab Pochodna benzotiadiazepiny, kompozycja farmaceutyczna zawierajaca pochodna benzotiadiazepiny oraz zastosowania pochodnej benzotiadiazepiny
GB0201850D0 (en) 2002-01-26 2002-03-13 Astrazeneca Ab Therapeutic treatment
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
GB0216321D0 (en) 2002-07-13 2002-08-21 Astrazeneca Ab Therapeutic treatment
CN100494185C (zh) 2002-08-28 2009-06-03 旭化成制药株式会社 新型季铵化合物
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
KR20070026392A (ko) 2004-02-27 2007-03-08 아사히 가세이 파마 가부시키가이샤 신규 벤조티아제핀 및 벤조티에핀 화합물
DE102005033099A1 (de) 2005-07-15 2007-01-18 Sanofi-Aventis Deutschland Gmbh Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindung enthaltende Arzneimittel und dessen Verwendung
DE102005033100B3 (de) 2005-07-15 2007-01-25 Sanofi-Aventis Deutschland Gmbh Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, diese Verbindung enthaltene Arzneimittel und Verfahren zu deren Herstellung
DE102006053635B4 (de) 2006-11-14 2011-06-30 Sanofi-Aventis Deutschland GmbH, 65929 Neue mit Benzylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
JO3131B1 (ar) 2010-04-27 2017-09-20 Glaxosmithkline Llc مركبات كيميائية
ES2586931T3 (es) 2010-11-04 2016-10-19 Albireo Ab Inhibidores de IBAT para el tratamiento de enfermedades hepáticas
BR112014010223B8 (pt) 2011-10-28 2021-02-23 Lumena Pharmaceuticals Llc uso de uma composição compreendendo inibidores de reciclagem de ácido de bílis e forma de dosagem pediátrica
KR101674806B1 (ko) 2014-10-20 2016-11-10 씨제이헬스케어 주식회사 신규한 아미노알킬벤조티아제핀 유도체 및 이의 용도
JP7391048B2 (ja) 2018-06-05 2023-12-04 アルビレオ・アクチボラグ ベンゾチア(ジ)アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
MX2020013839A (es) * 2018-06-20 2021-03-25 Albireo Ab Formulacion farmaceutica de odevixibat.
TWI835997B (zh) 2019-02-06 2024-03-21 瑞典商艾爾比瑞歐公司 苯并噻氮呯化合物及其用作膽酸調節劑之用途
RS63899B1 (sr) 2019-02-06 2023-02-28 Albireo Ab Benzotiadiazepinska jedinjenja i njihova upotreba kao modulatora žučnih kiselina
CA3129826A1 (en) * 2019-02-12 2020-08-20 Mirum Pharmaceuticals, Inc. Methods for treating cholestasis
AR120682A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzotiadiazepina y su uso como moduladores del ácido biliar
AR120679A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores ácido biliar
TWI867107B (zh) 2019-12-04 2024-12-21 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯化合物及其作為膽酸調節劑之用途
WO2021110887A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
WO2021110886A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2022029101A1 (en) 2020-08-03 2022-02-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
AU2021390172A1 (en) 2020-12-04 2023-06-22 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途

Similar Documents

Publication Publication Date Title
JP7010836B2 (ja) 胆汁鬱滞性疾患の処置の方法
US20230338392A1 (en) Subcutaneous administration of an asbt inhibitor
Kyriakidis et al. Plasmapheresis in the management of acute severe hyperlipidemic pancreatitis: report of 5 cases
KR102000332B1 (ko) 간내 담즙정체성 질환의 치료
US20240207286A1 (en) Asbt inhibitors in the treatment of renal diseases
KR20190015363A (ko) 간내 담즙 정체성 질환의 치료
CN113613640B (zh) 肾上腺素能β2受体激动剂R-对映体在治疗炎症性肠病及其肠外疾病的新应用
EP4153156A1 (en) Elafibranor for the treatment of primary sclerosing cholangitis
CN110538181B (zh) 酪氨酸激酶抑制剂在制备治疗急性肾损伤药物中的应用
RU2024129910A (ru) Подкожное введение ингибитора ASBT
Baumann et al. Effects of the ileal bile acid transport inhibitor A4250 on pruritus and serum bile acids in patients with biliary atresia: phase 2 study results
LAI et al. Papillary necrosis associated with rifampicin therapy
JP2024503861A (ja) 慢性腎疾患を処置する方法
WO2021097027A1 (en) Seladelpar for use in the treatment of alcoholic liver disease
RU2025113791A (ru) Ингибиторы ASBT в лечении заболеваний почек
Kimura et al. The surgical management of the unusual forms of biliary atresia
RU2815160C1 (ru) Способ профилактики поражения печени при остром панкреатите
JP7596548B2 (ja) 胆管症の治療
Pezzilli et al. Acute pancreatitis associated with myotonic dystrophy type I
Maslonka et al. Hypertriglyceridemia induced acute pancreatitis associated with diabetic ketoacidosis and a vaginal estrogen contraceptive device (NuvaRing): successfully treated with insulin infusion, plasmapheresis, and ring removal: 1316
王小健 Effect of low expression of PTHrp receptor on proliferation of tibial growth plate chondrocytes in chronic renal insufficiency young rats
HK40118120A (zh) 皮下给药asbt抑制剂
John et al. A Small Volume of Literature on High Volume Post-Obstructive Choleresis-a Rare Diagnosis: 1315
Bansal et al. Acute Pancreatitis Following Trans-arterial Chemo-embolization for Hepatocellular Carcinoma: 1314
HK40128340A (zh) 治疗肾脏疾病的asbt抑制剂